Piper Jaffray set a $62.00 price target on Aimmune Therapeutics (NASDAQ:AIMT) in a report published on Thursday. The firm currently has a buy rating on the biotechnology company’s stock.
A number of other research analysts have also commented on AIMT. Zacks Investment Research lowered shares of Aimmune Therapeutics from a buy rating to a hold rating in a research note on Wednesday, December 6th. BidaskClub lowered shares of Aimmune Therapeutics from a buy rating to a hold rating in a research note on Saturday, December 9th. Cantor Fitzgerald started coverage on shares of Aimmune Therapeutics in a research note on Tuesday, December 12th. They set an overweight rating and a $55.00 price objective on the stock. Robert W. Baird started coverage on shares of Aimmune Therapeutics in a research note on Wednesday, December 20th. They set an outperform rating and a $64.00 price objective on the stock. Finally, Credit Suisse Group set a $45.00 price objective on shares of Aimmune Therapeutics and gave the company a buy rating in a research note on Thursday, January 11th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Aimmune Therapeutics currently has a consensus rating of Buy and a consensus price target of $57.22.
NASDAQ AIMT opened at $29.41 on Thursday. Aimmune Therapeutics has a 12 month low of $15.97 and a 12 month high of $42.00.
Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($0.81) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.09). equities research analysts expect that Aimmune Therapeutics will post -2.72 earnings per share for the current year.
In related news, insider Daniel C. Md Adelman sold 9,933 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $40.00, for a total transaction of $397,320.00. Following the completion of the sale, the insider now directly owns 26,784 shares in the company, valued at $1,071,360. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Bakker Juliet Tammenoms bought 9,375 shares of Aimmune Therapeutics stock in a transaction that occurred on Thursday, February 22nd. The shares were acquired at an average price of $32.00 per share, with a total value of $300,000.00. Following the completion of the acquisition, the insider now directly owns 16,651 shares of the company’s stock, valued at approximately $532,832. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 58,093 shares of company stock valued at $1,858,976 and have sold 52,162 shares valued at $2,020,890. Company insiders own 24.56% of the company’s stock.
Large investors have recently modified their holdings of the stock. First Republic Investment Management Inc. bought a new stake in Aimmune Therapeutics during the fourth quarter worth approximately $202,000. SG Americas Securities LLC boosted its holdings in Aimmune Therapeutics by 54.7% during the third quarter. SG Americas Securities LLC now owns 8,430 shares of the biotechnology company’s stock worth $209,000 after buying an additional 2,979 shares in the last quarter. Virtu Financial LLC bought a new stake in Aimmune Therapeutics during the fourth quarter worth approximately $239,000. Daiwa SB Investments Ltd. boosted its holdings in Aimmune Therapeutics by 44.5% during the fourth quarter. Daiwa SB Investments Ltd. now owns 7,290 shares of the biotechnology company’s stock worth $276,000 after buying an additional 2,245 shares in the last quarter. Finally, Teacher Retirement System of Texas bought a new stake in Aimmune Therapeutics during the fourth quarter worth approximately $282,000. Hedge funds and other institutional investors own 65.92% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Aimmune Therapeutics (AIMT) Given a $62.00 Price Target at Piper Jaffray” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/08/aimmune-therapeutics-aimt-given-a-62-00-price-target-at-piper-jaffray.html.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.